Program
adimanebart
Also written as “ARGX-119”, “Adimanebart IV” and “ARGX-119 IV”.
Its studies are mostly in Muscular Atrophy, Spinal · Amyotrophic Lateral Sclerosis, led by argenx.
Furthest: phase 3, since Jul 30, 20266 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 64 open or running | phase 3since Jul 30, 2026 | Dec 20, 2022 | Dec 2026phase 1 · NCT07673601 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05670704 · 112 enrolled · Netherlands
- May 21, 2024Phase 1 study in Myasthenic Syndromes, CongenitalNCT06436742 · 15 enrolled · United States, Canada, France and more
- May 29, 2024Phase 2 study in Amyotrophic Lateral SclerosisNCT06441682 · 60 enrolled · Belgium, Canada, Denmark and more
- Dec 15, 2025Phase 2 study in Muscular Atrophy, SpinalNCT07287982 · 60 planned · United States, Australia, Canada and more
- Jun 23, 2026Phase 1 study in Healthy Volunteers (HV)NCT07673601 · 52 planned · Canada
- Jul 30, 2026Phase 3 study in Myasthenic Syndromes, CongenitalPhase 3 reachedNCT07746089 · 105 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy Volunteers (HV)NCT07673601
- Aug 24, 2027Primary completion: phase 1 study in Myasthenic Syndromes, CongenitalNCT06436742
- May 28, 2029Primary completion: phase 2 study in Muscular Atrophy, SpinalNCT07287982
- Oct 2030Primary completion: phase 3 study in Myasthenic Syndromes, CongenitalNCT07746089
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07746089Myasthenic Syndromes, Congenital | 3 | Not yet recruiting | Oct 2030 | 105 |
| NCT07673601Healthy Volunteers (HV) · Canada | 1 | Recruiting | Dec 2026 | 52 |
| NCT07287982Muscular Atrophy, Spinal · United States, Australia, Canada and more | 2 | Recruiting | May 28, 2029 | 60 |
| NCT06441682Amyotrophic Lateral Sclerosis · Belgium, Canada, Denmark and more | 2 | Terminated | Aug 12, 2026 | 60 |
| NCT06436742Myasthenic Syndromes, Congenital · United States, Canada, France and more | 1 | Active, not recruiting | Aug 24, 2027 | 15 |
| NCT05670704Healthy Volunteers · Netherlands | 1 | Completed | Aug 8, 2024 | 112 |
How it is read
Names in the registry
- “ARGX-119”, 3 entries
- “Adimanebart IV”, 2 entries
- “ARGX-119 IV”, 1 entry
Conditions, from the studies’ own filings
- Muscular Atrophy, Spinal, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.